Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Randomized, Double Blind, Non-inferiority, Comparative Study of the New Transdermal Patch Dosage Form Containing Loxoprofen Sodium (100 mg) and Loxonin® (60 mg Tablet) for the Treatment of Acute Traumatic Injuries

NCT02616068 is registered in ClinicalTrials.gov with Daiichi Sankyo Brasil Farmacêutica LTDA as lead sponsor.

NCT NCT02616068
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02616068 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Randomized, Double Blind, Non-inferiority, Comparative Study of the New Transdermal Patch Dosage Form Containing Loxoprofen Sodium (100 mg) and Loxonin® (60 mg Tablet) for the Treatment of Acute Traumatic Injuries
Lead sponsor
Daiichi Sankyo Brasil Farmacêutica LTDA
Phase
Phase 3
Overall status
Completed
Start date
October 31, 2015
Completion date
December 31, 2016
Enrollment
242 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

pain, trauma